Gilead Sciences, Inc

Closed
Call
Website

Photos

333 Lakeside Dr
Foster City, CA 94404
+1 (650) 574-3000
https://www.gilead.com
Founded in 1987, Gilead Sciences is one of the leaders in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA and RNA in the United States. The company discovers, develops and commercializes medications to advance the care of patients suffering from life-threatening diseases. Headquartered in Foster City, Calif., it serves North America, Europe and Australia and employs a staff of more than 3,400 individuals. Gilead Sciences areas of focus include antivirals, such as HIV/AIDS and chronic hepatitis, as well as cardiovascular conditions, including pulmonary arterial hypertension and resistant hypertension. The company also conducts studies on various respiratory diseases, such as influenza and cystic fibrosis.

Also at this address

Own this business?
See a problem?

You might also like

Drugs acting on the respiratory system, Blood derivatives, Surgical instruments and apparatus

Vaxart, Inc

Nabi Biopharmaceuticals develops and markets products that fight serious medical conditions. The company focuses on developing products that address commercial opportunities. Its main business areas encompass Gram-positive bacterial infections, hepatitis, kidney disease and nicotine addiction. Nabi Biopharmaceuticals product brands include PhosLo, Nabi-HB and Aloprim along with a number of products in various stages of clinical and pre-clinical development. Nabi Biopharmaceuticals maintains its international headquarters in Boca Raton, Fla., with principal research and development offices and laboratories in Rockville, Md. The company's European headquarters, Nabi Biopharmaceuticals Europe Limited, is located in Bray, Ireland.
Drugs acting on the respiratory system

Meissa Vaccines Inc

Meissa Vaccines Inc is a biotechnology company based in Redwood City, CA, dedicated to developing live attenuated vaccines for respiratory viruses such as RSV and COVID-19. Their innovative technologies, including the proprietary AttenuBlock platform, aim to deliver effective vaccines globally, preventing infection and generating a strong immune response. With a mission to safeguard people worldwide from life-threatening respiratory viruses, Meissa Vaccines focuses on developing safe and highly attenuated vaccine candidates that induce a better immune response than natural infection. Their RSV and COVID-19 vaccine candidates are designed to provide a durable immune response by stimulating mucosal IgA and serum neutralizing antibodies.Generated from the website
Coherus Oncology, Inc
Blood derivatives

Coherus Oncology, Inc

Coherus BioSciences, Inc., based in Redwood City, CA, is dedicated to advancing innovative cancer therapeutics, focusing on next-generation combination therapies to improve treatment outcomes for patients living with hard-to-treat tumors. The company offers a diverse portfolio of immuno-oncology therapies, including the FDA-approved toripalimab-tpzi, aimed at enhancing survival rates for individuals with recurrent or metastatic nasopharyngeal carcinoma. With a strong emphasis on clinical trials and research, Coherus is committed to developing multiple investigational drug candidates that target the tumor microenvironment. Their strategic transformation to Coherus Oncology underlines their exclusive focus on pioneering solutions to combat cancer and support patients in their treatment journeys. Generated from the website
United States›California›Foster City›Gilead Sciences, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.